New allergy-season focus as Perrigo’s Nasonex 24HR Allergy spray expands its reach

Nasonex 24HR Allergy, Perrigo’s over-the-counter version of mometasone furoate nasal spray, is positioned as a once-daily option for moderate to severe allergy sufferers in the US mass market. The spray targets nasal congestion and other symptoms with a steroid familiar from prescription use.

Edited by ad hoc news New Releases & Launches Desk. Reviewed before publication on 06/16/2026 at 5:55 AM ET. Details in the imprint.

Perrigo’s consumer health portfolio leans heavily on over-the-counter staples, and one of the key US launches in recent years sits squarely in the middle of allergy season: Nasonex 24HR Allergy, an over-the-counter mometasone furoate nasal spray derived from a long-standing prescription brand. The product is marketed as a once-daily treatment that relieves nasal congestion, sneezing and runny nose in adults and children 12 years and older, using a corticosteroid active ingredient known to allergy patients from its Rx predecessor. According to the official product information, each spray delivers 50 micrograms of mometasone furoate and the recommended dose for adults is two sprays in each nostril once per day, with relief building over several days of consistent use on the official product page.

Once-daily steroid spray aimed at moderate to severe allergy sufferers

Nasonex 24HR Allergy is part of Perrigo’s strategy to move established prescription molecules into the self-care aisle, with mometasone furoate nasal spray having been prescribed for allergic rhinitis for years before OTC switches became common. The pump bottle delivers a metered spray through a nasal applicator, and Perrigo highlights that the product is scent-free and alcohol-free to reduce irritation for frequent users. The formulation is indicated for the relief of upper respiratory allergy symptoms including nasal congestion, which distinguishes it from some older OTC antihistamine tablets that are less effective against stuffiness.

The dosing instructions reflect its steroid mechanism of action: users are advised that maximum effect may take several days of regular use rather than providing instant relief like some oral decongestants. On the US market, Nasonex 24HR Allergy is typically sold in sizes such as 60 and 120 sprays per bottle, with the larger pack covering up to 60 days of once-daily use for adults if administered as two sprays per nostril. Retailers including major drugstore chains and mass merchandisers list the spray in the allergy aisle, often positioned alongside other intranasal steroids such as fluticasone and budesonide, underlining the competitive nature of this category as more prescription brands transition to OTC status.

For Perrigo, Nasonex 24HR Allergy bolsters its over-the-counter allergy franchise that also includes private-label offerings, giving the company both a branded option and store-brand equivalents to serve different price points. The product fits into Perrigo’s broader self-care vision, which focuses on categories where consumers are willing to manage conditions like seasonal and perennial allergic rhinitis without visiting a physician for every refill. That strategic focus is reinforced by Perrigo’s emphasis in recent investor presentations on OTC switches and brand building in high-frequency categories such as allergy and pain relief, where repeat purchase behavior supports stable revenue streams as outlined in a recent Perrigo investor presentation.

Within the competitive nasal steroid segment, Nasonex 24HR Allergy differentiates itself through the mometasone molecule, which was historically perceived by some allergists as having a favorable balance between potency and systemic absorption when used as directed. The OTC packaging emphasizes 24-hour relief and once-daily dosing, appealing to users who prefer a simple regimen during high-pollen periods or when exposed to indoor allergens like pet dander and dust mites. For consumers comparing shelf options, factors such as perceived brand strength from its prescription heritage, neutral scent profile and price relative to generics typically shape the purchase decision, particularly for those managing symptoms over an entire season.

Perrigo positions Nasonex 24HR Allergy as a growth driver in its North American consumer self-care segment, where branded OTC products sit alongside a large portfolio of private-label remedies sold through leading retailers. The company has publicly framed the Nasonex OTC franchise as part of a cluster of "must-win" categories in allergy and respiratory care, which collectively contribute meaningfully to segment revenue and profitability according to coverage in FiercePharma. Shares of Perrigo Company PLC (IE00BGH1M568) traded on the NYSE at around $30 in recent sessions, reflecting the market’s view of its diversified OTC and nutrition portfolio rather than any single product line.

Nasonex 24HR Allergy in brief: key product facts

• Product: Nasonex 24HR Allergy (mometasone furoate nasal spray)
• Manufacturer: Perrigo Company PLC
• Category: New Release/Launch - OTC allergy nasal spray
• Launch date: US OTC launch following prescription heritage (exact year as per company disclosure)
• MSRP / Price: Varies by retailer; typically in the mid-range of branded OTC nasal steroids in the US
• Availability: Widely available in the United States through pharmacies, mass merchandisers and online retailers
• Target audience: Adults and children 12 years and older with seasonal or perennial allergic rhinitis seeking once-daily symptom control
• Key differentiator / USP: OTC nasal steroid based on the established mometasone prescription brand, with 24-hour relief and scent-free formulation.

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.